TMEM170A

Across TCGA pan-cancer cohorts, TMEM170A RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TMEM170A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where TMEM170A RNA is repressed in tumor relative to normal tissue. In most cancer types TMEM170A is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, STAD, and BLCA are the cancer types where TMEM170A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM170A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.472	<.001	9	view →
STAD	All	II,III,IV	+0.850	<.001	8	view →
BLCA	All	III,IV	+0.637	.003	6	view →
LUSC	All	II,III,IV	−0.454	<.001	6	view →
BRCA	Female	All	−0.404	<.001	6	view →
HNSC	All	All	+0.368	.002	6	view →
COAD	Female	All	−0.877	<.001	5	view →
KIRP	All	IV	+0.679	.003	5	view →
CHOL	Male	All	+1.208	<.001	4	view →
READ	All	All	−0.607	.002	3	view →
ESCA	All	II,III,IV	+1.500	.023	2	view →
LUAD	Female	III,IV	−0.462	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TMEM170A–THCA

Open the THCA breakdown →